Abstracts tagged "Nonsteroidal antiinflammatory drugs (NSAIDs) and psoriatic arthritis"

Abstract Number: 1681 • 2016 ACR/ARHP Annual Meeting
Beneficial Effect of n-3 Polyunsaturated Fatty Acids on Inflammation and Analgesic Use in Psoriatic Arthritis – a Randomised, Double Blind, Placebo-Controlled Trial
Salome Kristensen¹, Erik Berg Schmidt², Annette Schlemmer³, Claus Rasmussen⁴, Martin Berg Johansen⁵ and Jeppe Hagstrup Christensen⁶, ¹The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ²Cardiology, Aalborg University Hospital, Aalborg, Denmark, ³9Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ⁴Rheumatology, North Denmark Regional Hospital/Aalborg University, Hjoerring, Denmark, ⁵5Department of Cardiology and Unit of Clinical Biostatistics and Bioinformatics, Aalborg University Hospital, Aalborg, Denmark, ⁶Nephrology, Aalborg University Hospital, Aalborg, Denmark
Background/Purpose: Marine n-3 polyunsaturated fatty acids (PUFA) have anti-inflammatory effects and may be useful in the treatment of psoriatic arthritis. The effects of n-3 PUFA…
Abstract Number: 1717 • 2016 ACR/ARHP Annual Meeting
Progression of Radiographic Axial Damage in Patients with Psoriatic Arthritis. Relation with Clinical and Analytical Factors
Alba Quesada-Moreno¹, Maria Dolores Sanchez-González², Laura Pérez-Garrido³, Ricardo Usategui-Martín⁴, Guadalupe Manzano-Canabal¹, Cristina Hidalgo-Calleja¹, Olga Martínez-González¹, Javier Del Pino-Montes¹ and Carlos Alberto Montilla-Morales¹, ¹Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, ²HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, ³Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, SALAMANCA, Spain, ⁴IBSAL, SALAMANCA, Spain
Background/Purpose: Axial involvement in psoriatic arthritis (PsA) is a controversial issue. Lack of unanimity in the definition has led to a wide range of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].